Current Report Filing (8-k)
12 Oktober 2021 - 2:32PM
Edgar (US Regulatory)
0000822370
false
0000822370
2021-10-07
2021-10-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 7, 2021
Emmaus Life Sciences, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-35527
|
|
87-0419387
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
21250 Hawthorne Boulevard, Suite 800, Torrance, CA
|
|
90503
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area
code (310) 214-0065
(Former name or former address, if changed, since last
report.)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13a-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange
on which registered
|
|
None
|
|
|
|
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01. Entry into a Material Definitive Agreement
On October 7, 2021, Emmaus Life
Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) entered into
a License Agreement, effective as of October 6, 2021, with Kainos Medicine, Inc., a South Korean corporation (“Kainos”), under
which Kainos has granted us an exclusive license in the territory encompassing the U.S., the U.K. and the EU to patent rights, know-how
and other intellectual property relating to Kainos’s novel IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers,
including leukemia, lymphoma and solid tumor cancers. In consideration of the license, we have agreed in the License Agreement to pay
Kainos a six-figure upfront fee in cash, cash payments upon the achievement of specified milestones totaling in the mid-eight figures,
a single-digit percentage royalty based on net sales of the licensed products and a similar percentage of any sublicensing consideration.
The License Agreement will continue
on a licensed product-by-licensed product and country-by-country basis until the last to expire valid claim of any licensed patent in
such country.
On October 12, 2021, we issued
a press release regarding the License Agreement, a copy of which is included as Exhibit 99.1 to this Current Report and incorporated
herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
See the accompanying Index
to Exhibits, which information is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: October 12, 2021
|
Emmaus Life Sciences, Inc.
|
|
|
|
|
|
|
By:
|
/s/ YASUSHI NAGASAKI
|
|
|
|
Name: Yasushi Nagasaki
|
|
|
|
Title: Chief Financial Officer
|
INDEX TO EXHIBITS
3
Emmaus Life Sciences (QB) (USOTC:EMMA)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Emmaus Life Sciences (QB) (USOTC:EMMA)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
